Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juni 2025

Genmab — Juni 2025

Planlagt Fastgjort Låst Flyttet Genmab
266 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktør
    wrote on sidst redigeret af
    #176

    (Artiklen om Genmab kræver ikke abonnement)

    1 Reply Last reply
    0
    • BudweisB Offline
      BudweisB Offline
      Budweis
      wrote on sidst redigeret af
      #177

      Ser lovende ud https://ml-eu.globenewswire.com/Resource/Download/0b2cf0bd-906b-4985-b4ad-f7d8b772b972

      1 Reply Last reply
      0
      • BudweisB Offline
        BudweisB Offline
        Budweis
        wrote on sidst redigeret af
        #178

        Genmab Announces Epcoritamab Investigational Combination Therapy
        Demonstrates High Response Rates in Patients with Relapsed or
        Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for
        Autologous Stem Cell Transplantation (ASCT)

        1 Reply Last reply
        0
        • J Offline
          J Offline
          JKY_VH
          wrote on sidst redigeret af
          #179

          Super og mange tak for den Budweis:-)

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #180

            Epco fortsætter sin sejrsgang. Det bliver stort - ad åre.

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #181

              Lymphoma Hub
              @lymphomahub
              CONGRESS | #EHA2025 | PRESENTATION
              Daniel Kerr,
              @TGHCares presents updated results from the epcoritamab + pola-R-CHP cohort of the phase Ib/II EPCORE NHL-5
              trial (N = 37). https://x.com/lymphomahub/status/1934185493723263388

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #182

                "These promising results compare favorably to other regimens in 1L and may provide higher cure rates for patients with 1L DLBCL than SOC", suggesting that further exploration is warranted.

                1 Reply Last reply
                0
                • Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktør
                  wrote on sidst redigeret af
                  #183

                  Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) https://proinvestor.com/investornyt/1329270/genmab-announces-epcoritamab-investigational-combination-therapy-demonstrates-high-response-rates-in-patients-with-relapsed-or-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-eligible-for-autologous-stem-cell-trans

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #184

                    🙂

                    1 Reply Last reply
                    0
                    • SolsenS Offline
                      SolsenS Offline
                      Solsen
                      wrote on sidst redigeret af
                      #185

                      https://finance.yahoo.com/news/investigational-combination-first-class-bispecifics-071500581.html Flotte resultater på Genmab bispecific vi ser i NHL og MM. Specielt imponerede med epco i first line kombo.

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #186

                        Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease https://finance.yahoo.com/news/investigational-combination-first-class-bispecifics-071500581.html

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #187

                          sry that's the same one lol

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #188

                            Fixed-Duration Epcoritamab Plus Pola-R-CHP Demonstrates Durable Efficacy in First-Line DLBCL https://www.onclive.com/view/fixed-duration-epcoritamab-plus-pola-r-chp-demonstrates-durable-efficacy-in-first-line-dlbcl

                            1 Reply Last reply
                            0
                            • P Offline
                              P Offline
                              ProinvestorNEWS
                              wrote on sidst redigeret af
                              #189

                              Genmab har lovende resultater med kræftmiddel i lymfekræftform https://proinvestor.com/investornyt/1329375/genmab-har-lovende-resultater-med-kraeftmiddel-i-lymfekraeftform

                              1 Reply Last reply
                              0
                              • G Offline
                                G Offline
                                gentogen
                                wrote on sidst redigeret af
                                #190

                                "Lovende" er da vist en underdrivelse...

                                1 Reply Last reply
                                0
                                • R Offline
                                  R Offline
                                  Raun
                                  wrote on sidst redigeret af
                                  #191

                                  Ja enig - det er jo vildt imponerende 🙂

                                  1 Reply Last reply
                                  0
                                  • wisuwaW Offline
                                    wisuwaW Offline
                                    wisuwa
                                    wrote on sidst redigeret af
                                    #192

                                    Nå... Har været lidt fraværende i Genmab-regi. Hvad ser vi ind i nu? Hvad er kurstriggerne? Og nogle der har regnet på et
                                    EOY kursniveau? 🙂

                                    1 Reply Last reply
                                    0
                                    • Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktør
                                      wrote on sidst redigeret af
                                      #193

                                      Transactions in Connection with Share Buy-back Program https://proinvestor.com/investornyt/1329527/transactions-in-connection-with-share-buy-back-program

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #194

                                        EHA 2025: Genmab and AbbVie’s Epkinly outpaces BiTE rivals in r/r DLBCL trial https://finance.yahoo.com/news/eha-2025-genmab-abbvie-epkinly-134631049.html

                                        1 Reply Last reply
                                        0
                                        • P Offline
                                          P Offline
                                          ProinvestorNEWS
                                          wrote on sidst redigeret af
                                          #195

                                          Hej wisuwa...Du kan evt starte med at læse chathistorikken. 🙂 https://proinvestor.com/chathistory/-25/genmab

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper